Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review

Published:2023-09 Issue:9 Volume:29 Page:985-998
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Yin Yue¹,McDermott Cara²,Lockhart Catherine²

Affiliation:

1. Eshelman School of Pharmacy, University of North Carolina at Chapel Hill.

2. Biologics and Biosimilars Collective Intelligence Consortium, Alexandria, VA.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Reference41 articles.

1. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014

2. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

3. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP